|CEL-SCI moves higher on Israeli trial. After the bell: CMS to cover cost of Dendreon's Provenge|
|By BioMedReports.com Staff|
|Wednesday, 30 March 2011 18:51|
In extended trading shares of Dendreon traded as high as $37.00 before settling around $36.48, up 94 cents or 2.5%.
Shares of CEL-SCI Corporation (NYSE AMEX: CVM) gained nearly 10% today after the company announced that the State of Israel’s Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in that country. Israel is one of nine countries to participate in this global Phase III trial and will be conducted in approximately 48 clinical centers. CEL-SCI's partner Teva Pharmaceutical Industries will be conducting the trial at three clinical centers in Israel. The Phase III trial started in the United States in late December 2010 and is expected to commence in other countries around the world within the next 30-60 days. Multikine is the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
4.8 million shares traded hands as the stock gained 5 cents to $0.65.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that its Board of Directors has approved a two-for-one stock split, payable in the form of a 100 percent stock dividend. Separately, Alexion announced that it has been included in the NASDAQ-100 Index, effective April 4, 2011, prior to market open.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that enrollment of subjects in the second of two pivotal Phase III LibiGel (testosterone gel) safety and efficacy trials has been completed. Enrollment in the first LibiGel efficacy trial was completed in February. The efficacy trials are being conducted under an FDA-approved special protocol assessment agreement. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
Columbia Laboratories, Inc. (Nasdaq:CBRX) today announced that the Company expects results from the PREGNANT Study, a Phase III clinical trial evaluating PROCHIEVE (progesterone gel), will be published in a respected peer-reviewed medical journal online next week, and in the journal's print edition thereafter. The Company will issue a press release at the time of the online publication.
Medivation, Inc. (NASDAQ:MDVN) and Astellas Pharma Inc. today announced treatment of the first patient in the TERRAIN study, a Phase 2 comparison of the investigational drug MDV3100, a triple-acting oral androgen receptor antagonist, with bicalutamide, a commonly used anti-androgen, in the treatment of advanced prostate cancer patients who have progressed while on LHRH analogue therapy or following surgical castration.
"MDV3100 has been shown in preclinical studies to provide more complete suppression of the androgen receptor pathway than existing anti-androgens and the TERRAIN study provides the opportunity to investigate this finding further in a clinical setting," said Lynn Seely, M.D., chief medical officer of Medivation. "MDV3100 is currently in Phase 3 testing for advanced prostate cancer, but our goal is to determine if MDV3100 can benefit men with prostate cancer earlier in the course of the disease."
NewCardio, Inc., (OTC Bulletin Board:NWCI.ob) a cardiovascular diagnostic solutions developer, announced today that the Company has published a letter to shareholders providing an update regarding progress to date and management's objectives.
BAETA Corp. (OTCBB: BAEA) , an advanced technology-enabled health improvement company located in Fort Lee, New Jersey, announced today that it has received an investment from an Accredited institutional Investor.